Cardiometabolic Medicine

Cardiometabolic medicine sits at the intersection of cardiology, endocrinology and nephrology — the CKM (cardiovascular-kidney-metabolic) syndrome framework now defines this shared territory. Sessions cover GLP-1 and dual / triple incretin agonists, SGLT2 inhibitors across CKD and HF, finerenone in diabetic kidney disease, obesity-driven HFpEF, and the screening-and-prevention algorithm for the CKM population. Discussion addresses combination therapy sequencing, primary-care integration, payer dynamics and the rapidly expanding pipeline targeting metabolic and inflammatory pathways.